NASDAQ:HSIC - Henry Schein Stock Price, News, & Analysis

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Shares of Henry Schein split on the morning of Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly issued shares were issued to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein declared that its board has authorized a stock buyback plan on Tuesday, September 19th 2017, which allows the company to buyback $400,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to buy up to 6.3% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board believes its shares are undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) announced its quarterly earnings results on Monday, August, 6th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The company earned $3.33 billion during the quarter, compared to the consensus estimate of $3.31 billion. Henry Schein had a net margin of 3.15% and a return on equity of 20.40%. The firm's quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.88 EPS. View Henry Schein's Earnings History.

Henry Schein is scheduled to release their next quarterly earnings announcement on Monday, November 5th 2018. View Earnings Estimates for Henry Schein.

Henry Schein updated its FY18 earnings guidance on Monday, August, 6th. The company provided EPS guidance of $4.06-4.14 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.11.

19 brokers have issued 1 year target prices for Henry Schein's stock. Their predictions range from $66.00 to $102.00. On average, they anticipate Henry Schein's stock price to reach $83.00 in the next year. This suggests that the stock has a possible downside of 2.4%. View Analyst Price Targets for Henry Schein.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 1 sell rating, 10 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Henry Schein.

Henry Schein saw a drop in short interest during the month of September. As of September 14th, there was short interest totalling 16,020,723 shares, a drop of 7.3% from the August 31st total of 17,291,234 shares. Based on an average daily trading volume, of 1,103,270 shares, the short-interest ratio is presently 14.5 days. Currently, 10.6% of the company's stock are sold short. View Henry Schein's Current Options Chain.

Some companies that are related to Henry Schein include Vertex Pharmaceuticals (VRTX), HCA Healthcare (HCA), Humana (HUM), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Baxter International (BAX), BEXIMCO PHARMAC/S GDR REGS (BXP), FRESENIUS SE &/S (FSNUY), Edwards Lifesciences (EW), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), ESSILOR Intl S/S (ESLOY), Fresenius Medical Care AG & Co. (FMS), Align Technology (ALGN) and Alexion Pharmaceuticals (ALXN).

Henry Schein's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Swedbank (1.32%), Bank of Montreal Can (0.27%), Riverbridge Partners LLC (0.27%), Andra AP fonden (0.06%), Nisa Investment Advisors LLC (0.04%) and JLB & Associates Inc. (0.04%). Company insiders that own Henry Schein stock include Barry J Alperin, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Swedbank, Riverbridge Partners LLC, Neville Rodie & Shaw Inc., Gateway Investment Advisers LLC and Laurel Grove Capital LLC. Company insiders that have sold Henry Schein company stock in the last year include Barry J Alperin, Mark E Mlotek and Paul Brons. View Insider Buying and Selling for Henry Schein.

HSIC stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, CHURCHILL MANAGEMENT Corp, Andra AP fonden, Contravisory Investment Management Inc., Nisa Investment Advisors LLC, We Are One Seven LLC, Jaffetilchin Investment Partners LLC and Tandem Investment Advisors Inc.. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $85.07.

Henry Schein has a market capitalization of $13.02 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

The official website for Henry Schein is http://www.henryschein.com.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]